SecBot SecBot
PRESS-RELEASE ·Filed May 22, 2026

ONCY

Oncolytics Biotech, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

The ASCO presentation is a non-catalyst event, mechanistic data without new efficacy endpoints or regulatory milestones. Monitor for future registrational trial updates or partnership announcements, which are the primary value drivers for ONCY. The stock has historically shown high volatility on news, but this release lacks material clinical or financial content.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.8100
T+0 close · May 22, 2026 · via day close
Latest settled
+4.30%
T+60 · $0.8448
Vs SPY
+1.11%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 22 $0.8100entry
  2. T+1 · 6mo ago 0.00%α −0.59% · $0.8100
  3. T+5 · 6mo ago +30.86%α +29.19% · $1.06
  4. T+20 · 5mo ago +14.81%α +16.23% · $0.9300
  5. T+60 · 3mo ago +4.30%α +1.11% · $0.8448
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oncolytics Biotech announced translational data from the GOBLET and AWARE-1 trials will be presented at ASCO 2026, showing pelareorep expands pre-existing tumor-reactive immune cells and activates anti-tumor responses in KRAS-mutant pancreatic cancer and early-stage breast cancer. The data are mechanistic and non-clinical, with no new efficacy results or regulatory milestones disclosed.

Key Facts

  • Translational data from GOBLET (pancreatic cancer) and AWARE-1 (breast cancer) to be presented at ASCO 2026 (May 29-June 2).
  • Data show pelareorep induces antiviral immune response, expands virus-specific T cells, and activates tumor-specific T cells.
  • In pancreatic cancer, expansion of pre-existing TIL clones in blood correlated with reductions in tumor volume.
  • T-cell receptor sequencing confirmed expansion of mutant KRAS-specific T-cell clones.
  • In breast cancer biopsies, gene expression profiling showed increased antiviral/immune gene expression and CXCL13 induction linked to tertiary lymphoid structure formation.
  • No new clinical efficacy data (response rates, survival) or regulatory updates were disclosed.
  • Pelareorep has Fast Track designation from FDA for colorectal and pancreatic cancer.

Financial Impact

No financial figures disclosed; pre-revenue clinical-stage company with $94M market cap.

Risk Factors

  • Pelareorep remains investigational with no approved products; clinical trial failure risk is high.
  • Company is pre-revenue and dependent on capital markets for funding; dilution risk exists.
  • Translational data may not translate to clinical efficacy in registrational trials.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3300127

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 22, 2026